This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Madrigal's NASH Study Data Encouraging, Stock Skyrockets
by Zacks Equity Research
Madrigal Pharmaceuticals' (MDGL) thyroid hormone receptor, MGL-3196, achieves significantly sustained reduction in liver fat at week 36 in a phase II study evaluating it in NASH patients.
Gilead & Galapagos Announce Positive Data on Filgotinib
by Zacks Equity Research
Gilead (GILD) and partner Galapagaos (GLPG) announces positive data on filgotinib for the treatment of psoriatic arthritis in adults and ulcerative colitis.
Why Is Gilead Sciences (GILD) Down 7.2% Since Its Last Earnings Report?
by Zacks Equity Research
Gilead Sciences (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod
by Zacks Equity Research
The biotech sector grabbed headlines last week with drug approvals and licensing deals. Investors will await pipeline development news at the ASCO in the coming week.
bluebird's Lenti-D Gets Breakthrough Therapy Status From FDA
by Zacks Equity Research
bluebird (BLUE) obtained Breakthrough Therapy designation from the FDA for Lenti-D for the treatment of patients with cerebral adrenoleukodystrophy, which should expedite its development.
Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval
by Zacks Equity Research
Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.
Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag
by Zacks Equity Research
Intercept's (ICPT) first-quarter results were mixed as loss was narrower than expectations but sales missed expectations. The company also provided Ocaliva sales guidance for 2018.
The Zacks Analyst Blog Highlights: BP, Gilead, Enterprise Products and Colgate
by Zacks Equity Research
The Zacks Analyst Blog Highlights: BP, Gilead, Enterprise Products and Colgate
Celgene (CELG) Q1 Earnings & Sales Beat on Revlimid Strength
by Zacks Equity Research
Celgene (CELG) surpasses both earnings and sales estimates in the first quarter on the back of impressive performance from Pomalyst and Otezla.
5 Value Stocks to Book Gains Using Price-to-Book Ratio
by Zacks Equity Research
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.
Top Stock Reports for BP, Gilead, Enterprise Products & Colgate
by Mark Vickery
Today's Research Daily features new research reports on 17 major stocks, including BP (BP), Gilead (GILD), Enterprise Products (EPD) and Colgate (CL).
Company News for May 3, 2018
by Zacks Equity Research
Companies in The News are: SNAP,GILD,MA,UNM
The Zacks Analyst Blog Highlights: Apple, Snap, Gilead and T-Mobile U.S.
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Snap, Gilead and T-Mobile U.S.
Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1
by Zacks Equity Research
The biotech sector was in focus over the last five trading sessions as several bigwigs like Gilead and Vertex, among others reported results while some others provided pipeline updates.
Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV
by Zacks Equity Research
Gilead (GILD) announced dismal results for the first-quarter as HCV sales plunged further due to increasing competition.
Apple (AAPL) iPhone Sales Off the Mark, Shares Up; Also SNAP, GILD & TMUS
by Mark Vickery
Earnings topped the Zacks consensus by 4 cents to $2.73 per share on $61.1 billion in sales.
Gilead (GILD) Shares Slip on Earnings Miss, Revenues Down Over 20%
by Madeleine Johnson
Gilead Sciences Inc. (GILD) just released its latest quarterly financial results, posting earnings of $1.48 and revenues of $5.1 billion.
Is a Beat in the Cards for Agios (AGIO) in Q1 Earnings?
by Zacks Equity Research
Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investor focus is expected to remain on the company's pipeline in the first quarter.
What's in Store for ImmunoGen (IMGN) This Earnings Season?
by Zacks Equity Research
ImmunoGen's (IMGN) considerable progress with lead pipeline candidate, mirvetuximab soravtansine, might drive the stock in Q1.
Will Agenus (AGEN) Disappoint Investors This Earnings Season?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report first-quarter 2018 on May 3 and the company will focus on its pipeline candidates and provide updates on them.
HIV Segment to Aid Gilead (GILD) Beat Q1 Earnings Estimates?
by Zacks Equity Research
Gilead (GILD) is likely to report an earnings beat in the first-quarter (results due on May 1) driven by its HIV franchise strength.
What's in the Cards for Conatus (CNAT) This Earnings Season?
by Zacks Equity Research
Conatus' (CNAT) might see improvement in Q1 courtesy of its lead candidate emricasan. However, the company's portfolio is devoid of an approved product and its resulting revenues.
Glaxo (GSK) Q1 Earnings Lag, Shingrix Vaccines Sales Solid
by Zacks Equity Research
Glaxo's (GSK) Q1 earnings fall short of estimates while revenues rise year over year. The company's vaccine segment performs strongly on the back of Shingrix sales.
Is a Beat in the Cards for Gilead (GILD) in Q1 Earnings?
by Zacks Equity Research
Gilead (GILD) is likely to beat earnings estimates when it reports first-quarter results on May 1 driven by strong HIV sales.
What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?
by Zacks Equity Research
During the earnings call, we expect Immune Design to shed light on the progress of its pipeline candidates-CMB305 and G100 .